

# Michel Komajda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3837280/publications.pdf>

Version: 2024-02-01

251  
papers

42,932  
citations

3731

89  
h-index

2178

202  
g-index

268  
all docs

268  
docs citations

268  
times ranked

28936  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 326-336.	1.6	222
2	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 117-128.	27.0	1,080
3	Asymptomatic left ventricular dysfunction in patients with type 2 diabetes free of cardiovascular disease and its relationship with clinical characteristics: The <sc>DIACAR</sc> cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 434-443.	4.4	7
4	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. <i>ESC Heart Failure</i> , 2021, 8, 861-871.	3.1	20
5	Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23. <i>European Heart Journal</i> , 2021, 42, 2000-2011.	2.2	49
6	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	3.9	32
7	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , 2021, 144, 1284-1294.	1.6	195
8	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	2.2	2,811
9	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 196-213.	7.1	131
10	Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials. <i>Circulation: Heart Failure</i> , 2020, 13, e006720.	3.9	22
11	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	7.1	155
12	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 601-612.	2.8	97
13	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 974-984.	7.1	52
14	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1279-1287.	7.1	205
15	Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.. <i>ESC Heart Failure</i> , 2019, 6, 1199-1207.	3.1	11
16	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 418-427.	4.1	20
17	Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2019, 21, 921-929.	7.1	86
18	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006539.	3.9	78

#	ARTICLE	IF	CITATIONS
19	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 853-872.	7.1	434
20	The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 377-387.	1.8	12
21	Role of ivabradine in management of stable angina in patients with different clinical profiles. <i>Open Heart</i> , 2018, 5, e000725.	2.3	10
22	Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. <i>European Journal of Heart Failure</i> , 2018, 20, 373-381.	7.1	41
23	Pregnancy in women with a cardiomyopathy: Outcomes and predictors from a retrospective cohort. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 199-209.	1.6	32
24	Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 1315-1322.	7.1	96
25	Diabète et insuffisance cardiaque : données épidémiologiques et implications thérapeutiques.. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 909-917.	0.0	1
26	Efficacité et effets indésirables des statines : évidences et politiques. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 817-835.	0.0	0
27	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , 2017, 38, ehw509.	2.2	36
28	Liraglutide in heart failure: caution is needed. <i>European Journal of Heart Failure</i> , 2017, 19, 78-79.	7.1	4
29	Patient journey in decompensated heart failure: An analysis in departments of cardiology and geriatrics in the Greater Paris University Hospitals. <i>Archives of Cardiovascular Diseases</i> , 2017, 110, 42-50.	1.6	18
30	Comments on meta-analysis of ivabradine as adjuvant treatment for chronic heart failure by Mizzaci et al.. <i>International Journal of Cardiology</i> , 2017, 239, 2.	1.7	0
31	Effect of intracoronary administration of <sc>AAV1</sc>/<sc>SERCA2a</sc> on ventricular remodelling in patients with advanced systolic heart failure: results from the <sc>AGENTâ€HF</sc> randomized phase 2 trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1534-1541.	7.1	75
32	Effect of ivabradine in patients with heart failure with preserved ejection fraction: the <sc>EDIFY</sc> randomized placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1495-1503.	7.1	154
33	Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the <sc>QUALIFY</sc> international registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1414-1423.	7.1	183
34	Heart rate and its reduction in chronic heart failure and beyond. <i>European Journal of Heart Failure</i> , 2017, 19, 1230-1241.	7.1	37
35	Brain natriuretic peptide usefulness in very elderly dyspnoeic patients: the BED study. <i>European Journal of Heart Failure</i> , 2017, 19, 540-548.	7.1	28
36	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2017, 135, 724-735.	1.6	153

#	ARTICLE	IF	CITATIONS
37	Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 233-246.	2.6	108
38	Financial impact of ivabradine on reducing heart failure penalties under the Hospital Readmission Reduction Program. <i>Current Medical Research and Opinion</i> , 2017, 33, 185-191.	1.9	2
39	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017, 23, 20-28.	1.7	35
40	Quality of Physician Adherence to Guideline Recommendations for Life-saving Treatment in Heart Failure: an International Survey. <i>Cardiac Failure Review</i> , 2017, 3, 130.	3.0	12
41	Exome-wide association study reveals novel susceptibility genes to sporadic dilated cardiomyopathy. <i>PLoS ONE</i> , 2017, 12, e0172995.	2.5	92
42	Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. <i>European Heart Journal</i> , 2016, 37, ehv481.	2.2	140
43	Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2016, 22, 1064-1071.	0.9	2
44	Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2016, 18, 328-336.	7.1	88
45	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , 2016, 18, 672-683.	7.1	21
46	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (Iâ€PRESERVE) trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1021-1031.	7.1	17
47	Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a postâ€hoc analysis of <sc>SHIFT</sc>. <i>European Journal of Heart Failure</i> , 2016, 18, 1182-1189.	7.1	39
48	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.8	26
49	Physicians' adherence to guidelineâ€recommended medications in heart failure with reduced ejection fraction: data from the <sc>QUALIFY</sc> global survey. <i>European Journal of Heart Failure</i> , 2016, 18, 514-522.	7.1	193
50	Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. <i>European Heart Journal</i> , 2016, 37, 1850-1858.	2.2	757
51	The year in cardiology 2015: heart failure. <i>European Heart Journal</i> , 2016, 37, 437-441.	2.2	2
52	How can the European Society of Cardiology ensure compliance with ethical standards?. <i>European Heart Journal</i> , 2016, 37, 741-744.	2.2	4
53	EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). <i>European Heart Journal</i> , 2016, 37, 152-160.	2.2	29
54	Maladies rares, le modÃˆle franÃ§ais. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2016, 200, 979-991.	0.0	0

#	ARTICLE	IF	CITATIONS
55	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the PReserve study. <i>European Journal of Heart Failure</i> , 2015, 17, 809-817.	7.1	52
56	Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1294-1301.	7.1	58
57	Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. <i>European Journal of Heart Failure</i> , 2015, 17, 925-935.	7.1	203
58	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. <i>European Journal of Heart Failure</i> , 2015, 17, 1182-1191.	7.1	48
59	Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model. <i>International Journal of Cardiology</i> , 2015, 184, 163-169.	1.7	38
60	Heart rate in chronic heart failure: an overlooked risk factor. <i>European Heart Journal</i> , 2015, 36, 648-649.	2.2	5
61	Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 169-176.	7.1	36
62	Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. <i>European Journal of Heart Failure</i> , 2015, 17, 518-526.	7.1	54
63	Effect of Ivabradine on Early Readmissions After Hospitalization for Worsening Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 268-269.	4.1	3
64	Involvement of BAG3 and HSPB7 loci in various etiologies of systolic heart failure: Results of a European collaboration assembling more than 2000 patients. <i>International Journal of Cardiology</i> , 2015, 189, 105-107.	1.7	22
65	The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 429-441.	4.1	72
66	A 22-Year Follow-up Study of Long-term Cardiac Outcome and Predictors of Survival in Friedreich Ataxia. <i>JAMA Neurology</i> , 2015, 72, 1334.	9.0	69
67	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina. <i>Circulation: Heart Failure</i> , 2015, 8, 717-724.	3.9	22
68	Unresolved issues in the management of chronic stable angina. <i>International Journal of Cardiology</i> , 2015, 201, 200-207.	1.7	27
69	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 478-486.	4.1	21
70	Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial). <i>American Journal of Cardiology</i> , 2015, 116, 1890-1897.	1.6	54
71	International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. <i>Circulation</i> , 2015, 131, 43-53.	1.6	75
72	Atlas of the clinical genetics of human dilated cardiomyopathy. <i>European Heart Journal</i> , 2015, 36, 1123-1135.	2.2	456

#	ARTICLE	IF	CITATIONS
73	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. <i>European Heart Journal</i> , 2015, 36, 657-668.	2.2	902
74	Le point sur le dictionnaire de l'ANM du 1er janvier 2015 au 26 septembre 2016. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2015, 199, 1493-1498.	0.0	0
75	[Not Available]. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2015, 199, 835-847.	0.0	0
76	A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 1069-1077.	2.2	137
77	Left atrial volume predicts abnormal exercise left ventricular filling pressure. <i>European Journal of Heart Failure</i> , 2014, 16, 1089-1095.	7.1	19
78	Below-Knee Arterial Calcification in Type 2 Diabetes: Association With Receptor Activator of Nuclear Factor $\kappa$ B Ligand, Osteoprotegerin, and Neuropathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4250-4258.	3.6	18
79	Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in <scp>SHIFT</scp>. <i>European Journal of Heart Failure</i> , 2014, 16, 810-816.	7.1	58
80	History of Atrial Fibrillation as a Risk Factor in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 960-966.	3.9	35
81	The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from <scp>SHIFT</scp>. <i>European Journal of Heart Failure</i> , 2014, 16, 426-434.	7.1	42
82	Rationale and design of the CONFIRMâ€CHF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. <i>ESC Heart Failure</i> , 2014, 1, 52-58.	3.1	38
83	Sustainable Development Goals and the Future of Cardiovascular Health: A Statement From the Global Cardiovascular Disease Taskforce. <i>Journal of the American Heart Association</i> , 2014, 3, e000504.	3.7	28
84	Efficacy and Safety of Ivabradine in Patients With Severe Chronic Systolic Heart Failure (from the Tj ETQqO O O rgBT /Overlock_10 Tf 50	1.6	45
85	Heart failure with preserved ejection fraction: a clinical dilemma. <i>European Heart Journal</i> , 2014, 35, 1022-1032.	2.2	178
86	A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 1175-1182.	7.1	64
87	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (lâ€Preserve). <i>European Journal of Heart Failure</i> , 2014, 16, 778-787.	7.1	80
88	Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1106-1113.	2.8	67
89	The Atrial Fibrillation Ablation Pilot Study: an European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. <i>European Heart Journal</i> , 2014, 35, 1466-1478.	2.2	180
90	Prevalence of Memory Disorders in Ambulatory Patients Aged $\geq 70$ Years With Chronic Heart Failure (from the EFICARE Study). <i>American Journal of Cardiology</i> , 2014, 113, 1205-1210.	1.6	34

#	ARTICLE	IF	CITATIONS
91	Pretest probability of a normal echocardiography: Validation of a simple and practical algorithm for routine use. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 105-111.	1.6	2
92	Sustainable Development Goals and the Future of Cardiovascular Health: A Statement From the Global Cardiovascular Disease Taskforce. <i>Global Heart</i> , 2014, 9, 273.	2.3	18
93	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. <i>ESC Heart Failure</i> , 2014, 1, n/a-n/a.	3.1	1
94	Sustainable Development Goals and the future of cardiovascular health. A statement from the Global Cardiovascular Disease Taskforce. <i>European Heart Journal</i> , 2014, 35, 3238-9.	2.2	5
95	The wealth of nations and the dissemination of cardiovascular research. <i>International Journal of Cardiology</i> , 2013, 169, 190-195.	1.7	7
96	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , 2013, 18, 107-122.	3.9	51
97	Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. <i>European Heart Journal</i> , 2013, 34, 2149-2157.	2.2	225
98	Selective Heart Rate Reduction With Ivabradine Unloads the Left Ventricle in Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1977-1985.	2.8	104
99	Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 79-84.	7.1	24
100	Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. <i>European Journal of Heart Failure</i> , 2013, 15, 1296-1303.	7.1	63
101	A novel genetic variant in the transcription factor Islet-1 exerts gain of function on myocyte enhancer factor 2C promoter activity. <i>European Journal of Heart Failure</i> , 2013, 15, 267-276.	7.1	21
102	Risk following hospitalization in stable chronic systolic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 885-891.	7.1	42
103	Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 303-323.	1.6	48
104	Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. <i>European Heart Journal</i> , 2013, 34, 2263-2270.	2.2	85
105	Screening of genes encoding junctional candidates in arrhythmogenic right ventricular cardiomyopathy/dysplasia. <i>Europace</i> , 2013, 15, 1522-1525.	1.7	19
106	Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 1044-1052.	7.1	22
107	Championing cardiovascular health innovation in Europe. <i>Acta Cardiologica</i> , 2013, 68, 650-655.	0.9	1
108	Desmosomal Cadherins Are Decreased in Explanted Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patient Hearts. <i>PLoS ONE</i> , 2013, 8, e75082.	2.5	21

#	ARTICLE	IF	CITATIONS
109	L'Éducation thérapeutique du patient (ETP), une pièce maîtresse pour répondre aux nouveaux besoins de la médecine. Bulletin De L'Academie Nationale De Medecine, 2013, 197, 1747-1781.	0.0	4
110	Renal Dysfunction in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction. Circulation: Heart Failure, 2012, 5, 309-314.	3.9	152
111	Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2012, 5, 571-578.	3.9	177
112	Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial. Circulation: Heart Failure, 2012, 5, 217-225.	3.9	63
113	Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal, 2012, 33, 2813-2820.	2.2	126
114	The beat goes on: on the importance of heart rate in chronic heart failure. European Heart Journal, 2012, 33, 1044-1045.	2.2	7
115	Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis. European Journal of Heart Failure, 2012, 14, 1139-1146.	7.1	100
116	Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. European Journal of Heart Failure, 2012, 14, 1401-1409.	7.1	25
117	From abstract to impact in cardiovascular research: factors predicting publication and citation. European Heart Journal, 2012, 33, 3034-3045.	2.2	66
118	Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose?. Journal of the American College of Cardiology, 2012, 59, 1938-1945.	2.8	233
119	Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal, 2012, 33, 2290-2296.	2.2	144
120	A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. European Heart Journal, 2011, 32, 1065-1076.	2.2	292
121	Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform: Report of a policy conference of the European Society of Cardiology. European Heart Journal, 2011, 32, 1673-1686.	2.2	73
122	Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. European Journal of Heart Failure, 2011, 13, 1253-1260.	7.1	32
123	Heart rate decrease: A new paradigm in the treatment of heart failure. Insights from the SHIFT study. Archives of Cardiovascular Diseases, 2011, 104, 67-69.	1.6	3
124	Clinical development of pharmacologic agents for acute heart failure syndromes: A proposal for a mechanistic translational phase. American Heart Journal, 2011, 161, 224-232.	2.7	38
125	Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2011, 4, 27-35.	3.9	216
126	Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2011, 4, 561-568.	3.9	91

#	ARTICLE	IF	CITATIONS
127	Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 569-577.	3.9	219
128	Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction. <i>Circulation</i> , 2011, 124, 2491-2501.	1.6	418
129	Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes. <i>Diabetes Care</i> , 2011, 34, 1394-1396.	8.6	28
130	The future of clinical trials in secondary prevention after acute coronary syndromes. <i>European Heart Journal</i> , 2011, 32, 1583-1589.	2.2	27
131	Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. <i>European Heart Journal</i> , 2011, 32, 2395-2404.	2.2	175
132	Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. <i>European Heart Journal</i> , 2011, 32, 2507-2515.	2.2	264
133	Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. <i>Circulation: Heart Failure</i> , 2010, 3, 314-325.	3.9	134
134	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. <i>Lancet</i> , The, 2010, 376, 875-885.	13.7	2,119
135	Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction. <i>Circulation</i> , 2010, 121, 1393-1405.	1.6	290
136	Myocarditis during Acute Schistosomiasis in Two Travelers. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 82, 365-367.	1.4	19
137	The current and future management of acute heart failure syndromes. <i>European Heart Journal</i> , 2010, 31, 784-793.	2.2	100
138	Genetic Association Study Identifies HSPB7 as a Risk Gene for Idiopathic Dilated Cardiomyopathy. <i>PLoS Genetics</i> , 2010, 6, e1001167.	3.5	110
139	Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I <sub>β</sub> Inhibitor Ivabradine Trial (SHIFT). <i>European Journal of Heart Failure</i> , 2010, 12, 75-81.	7.1	88
140	Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 239-248.	7.1	214
141	Early identification of mutation carriers in familial hypertrophic cardiomyopathy by combined echocardiography and tissue Doppler imaging. <i>European Heart Journal</i> , 2010, 31, 1599-1607.	2.2	36
142	Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. <i>European Heart Journal</i> , 2010, 31, 824-831.	2.2	203
143	Coenzyme Q10, Rosuvastatin, and Clinical Outcomes in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1196-1204.	2.8	105
144	Long-term outcome after bare-metal or drug-eluting stenting for allograft coronary artery disease. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 316-322.	0.6	17

#	ARTICLE	IF	CITATIONS
145	Predictors of short term mortality in heart failure – Insights from the Euro Heart Failure survey. International Journal of Cardiology, 2010, 138, 63-69.	1.7	51
146	Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial. Journal of Cardiac Failure, 2010, 16, 128-134.	1.7	53
147	Predicting Adverse Effects during Angiotensin Receptor Blocker Treatment in Heart Failure: Results from the HEAAL Trial. Journal of Cardiac Failure, 2010, 16, S73-S74.	1.7	0
148	Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet, The, 2010, 376, 886-894.	13.7	769
149	Ivabradine and outcomes in chronic heart failure – Authors' reply. Lancet, The, 2010, 376, 2069-2070.	13.7	3
150	Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. European Heart Journal, 2009, 30, 3015-3026.	2.2	117
151	A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy. European Heart Journal, 2009, 30, 1648-1655.	2.2	39
152	Mutations in the ANKRD1 gene encoding CARP are responsible for human dilated cardiomyopathy. European Heart Journal, 2009, 30, 2128-2136.	2.2	66
153	Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. European Journal of Heart Failure, 2009, 11, 85-91.	7.1	51
154	Years needed to treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. European Journal of Heart Failure, 2009, 11, 256-263.	7.1	11
155	Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. European Journal of Heart Failure, 2009, 11, 281-291.	7.1	120
156	Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). American Heart Journal, 2009, 157, 271-277.	2.7	141
157	Consensus of the French Society of Gerontology and Geriatrics and the French Society of Cardiology for the management of coronary artery disease in older adults. Archives of Cardiovascular Diseases, 2009, 102, 829-845.	1.6	21
158	Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet, The, 2009, 373, 2125-2135.	13.7	1,243
159	Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet, The, 2009, 374, 1840-1848.	13.7	548
160	The development of an international, common, prospective, cardiology database. Report of the joint G8 Cardio-Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO)–Societ� Fran�saise de Cardiologie (SFC) database committee. Acute Cardiac Care, 2009, 11, 113-20.	0.2	1
161	Feasibility of outpatient coronary angiography with –ad hoc–angioplasty. Archives of Cardiovascular Diseases, 2008, 101, 383-390.	1.6	5
162	Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. New England Journal of Medicine, 2008, 359, 2456-2467.	27.0	1,663

#	ARTICLE	IF	CITATIONS
163	Health Related Quality of Life in I-PRESERVE Trial. <i>Journal of Cardiac Failure</i> , 2008, 14, S73.	1.7	0
164	A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. <i>European Heart Journal</i> , 2008, 29, 816-824.	2.2	131
165	New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. <i>European Heart Journal</i> , 2008, 29, 1618-1624.	2.2	127
166	Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. <i>European Journal of Heart Failure</i> , 2008, 10, 149-156.	7.1	183
167	Cardiologists' awareness and perceptions of guidelines for chronic heart failure. The ADDRESS your Heart survey. <i>European Journal of Heart Failure</i> , 2008, 10, 1020-1025.	7.1	33
168	Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. <i>European Journal of Heart Failure</i> , 2008, 10, 140-148.	7.1	134
169	Design of the Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan (HEAAL) study in patients intolerant to ACE-inhibitor. <i>European Journal of Heart Failure</i> , 2008, 10, 899-906.	7.1	18
170	Mutations in the Z-band protein myopalladin gene and idiopathic dilated cardiomyopathy. <i>Cardiovascular Research</i> , 2008, 77, 118-125.	3.8	99
171	Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. <i>European Heart Journal</i> , 2008, 30, 478-486.	2.2	247
172	State of the art: Using natriuretic peptide levels in clinical practice. <i>European Journal of Heart Failure</i> , 2008, 10, 824-839.	7.1	691
173	Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. <i>Critical Care Medicine</i> , 2008, 36, S129-S139.	0.9	240
174	Familial and sporadic hypertrophic myopathy: differences and similarities in a genotyped population. A long follow-up study. <i>Revista Portuguesa De Cardiologia</i> , 2008, 27, 147-73.	0.5	10
175	Effects of Torcetrapib in Patients at High Risk for Coronary Events. <i>New England Journal of Medicine</i> , 2007, 357, 2109-2122.	27.0	2,811
176	Rosuvastatin in Older Patients with Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2007, 357, 2248-2261.	27.0	1,330
177	Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2007, 9, 684-694.	7.1	335
178	Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a $\beta$ -blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial. <i>European Journal of Heart Failure</i> , 2007, 9, 795-801.	7.1	69
179	Recall of lifestyle advice in patients recently hospitalised with heart failure: A EuroHeart Failure Survey analysis. <i>European Journal of Heart Failure</i> , 2007, 9, 1095-1103.	7.1	58
180	International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: Data from the EuroHeart Failure Survey. <i>European Journal of Heart Failure</i> , 2007, 9, 292-299.	7.1	61

#	ARTICLE	IF	CITATIONS
181	Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 1128-1135.	7.1	36
182	Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. <i>European Journal of Heart Failure</i> , 2007, 9, 901-909.	7.1	85
183	Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. <i>European Heart Journal</i> , 2007, 28, 1310-1318.	2.2	103
184	A familial form of conduction defect related to a mutation in the PRKAG2 gene. <i>Europace</i> , 2007, 9, 597-600.	1.7	13
185	Treatment of advanced chronic heart failure with normal left ventricular ejection fraction. Response to the letter by Dr. Martinez-Selles. <i>European Journal of Heart Failure</i> , 2007, 9, 1224-1225.	7.1	2
186	Rosiglitazone Evaluated for Cardiovascular Outcomes – An Interim Analysis. <i>New England Journal of Medicine</i> , 2007, 357, 28-38.	27.0	729
187	Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 963-971.	2.8	62
188	The Safety of Amiodarone in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2007, 13, 340-345.	1.7	52
189	EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. <i>European Heart Journal</i> , 2006, 27, 2725-2736.	2.2	1,063
190	A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the ‘‘Patient Journey’’) in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1603-1611.	2.8	66
191	The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. <i>European Heart Journal</i> , 2006, 27, 1440-1446.	2.2	201
192	Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). <i>European Heart Journal</i> , 2006, 27, 1216-1222.	2.2	294
193	Severe dilated cardiomyopathy and quadriceps myopathy due to lamin A/C gene mutation: A phenotypic study. <i>European Journal of Heart Failure</i> , 2006, 8, 249-256.	7.1	22
194	Molecular genetics in hypertrophic cardiomyopathy: towards individualized management of the disease. <i>Expert Review of Molecular Diagnostics</i> , 2006, 6, 65-78.	3.1	24
195	Lessons from the European heart survey. <i>Circulation</i> , 2006, 113, f25-6.	1.6	1
196	Comparative Value of Tissue Doppler Imaging and M-Mode Color Doppler Mitral Flow Propagation Velocity for the Evaluation of Left Ventricular Filling Pressure. <i>Chest</i> , 2005, 128, 2544-2550.	0.8	36
197	Exchange of $\beta$ -blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Tj ETQq1 1 0.784314 rgBT /Dv	7.1	29
198	The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology: Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: reply. <i>European Heart Journal</i> , 2005, 26, 2473-2474.	2.2	25

#	ARTICLE	IF	CITATIONS
199	Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). European Heart Journal, 2005, 26, 1115-1140.	2.2	1,986
200	Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. European Heart Journal, 2005, 26, 384-416.	2.2	1,114
201	Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. European Heart Journal, 2005, 26, 1303-1308.	2.2	564
202	Mutation screening in dilated cardiomyopathy: prominent role of the beta myosin heavy chain gene. European Heart Journal, 2005, 26, 794-803.	2.2	135
203	Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. European Heart Journal, 2005, 26, 1653-1659.	2.2	354
204	Diagnostic accuracy of a 2D left ventricle hypertrophy score for familial hypertrophic cardiomyopathy. European Heart Journal, 2005, 26, 1882-1886.	2.2	10
205	Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. European Heart Journal, 2005, 26, 2706-2713.	2.2	172
206	Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. European Heart Journal, 2005, 26, 2259-2268.	2.2	154
207	Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET. American Heart Journal, 2005, 149, 370-376.	2.7	74
208	The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial: Rationale and Design. Journal of Cardiac Failure, 2005, 11, 576-585.	1.7	129
209	ESSENTIAL—The Studies of Oral Enoximone Therapy in Advanced Heart Failure. Journal of Cardiac Failure, 2005, 11, 721.	1.7	2
210	Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. European Heart Journal, 2004, 25, 1788-1796.	2.2	97
211	Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol) Tj ETQq1 1 0.784314 rgBT /Overlock 62	7.1	62
212	The Benefits of Early Combination Treatment of Carvedilol and an ACE-Inhibitor in Mild Heart Failure and Left Ventricular Systolic Dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN). Cardiovascular Drugs and Therapy, 2004, 18, 57-66.	2.6	123
213	A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET). Cardiovascular Drugs and Therapy, 2004, 18, 139-152.	2.6	11
214	Prevalence of anemia in patients with chronic heart failure and their clinical characteristics. Journal of Cardiac Failure, 2004, 10, S1-S4.	1.7	63
215	Impact on mortality of plasma NT-proBNP in chronic heart failure in patients treated with beta-blockers. results from COMET. Journal of Cardiac Failure, 2004, 10, S77.	1.7	0
216	Functional consequences of an LMNA mutation associated with a new cardiac and non-cardiac phenotype. Human Mutation, 2003, 21, 473-481.	2.5	66

#	ARTICLE	IF	CITATIONS
217	Polymorphisms of genes of the cardiac calcineurin pathway and cardiac hypertrophy. <i>European Journal of Human Genetics</i> , 2003, 11, 659-664.	2.8	27
218	Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. <i>American Heart Journal</i> , 2003, 146, 729-735.	2.7	48
219	Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2003, 107, 2227-2232.	1.6	1,129
220	Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. <i>Lancet</i> , The, 2003, 362, 7-13.	13.7	1,664
221	Apical left ventricular aneurysm without atrio-ventricular block due to a lamin A/C gene mutation. <i>European Journal of Heart Failure</i> , 2003, 5, 821-825.	7.1	39
222	Genes and their polymorphisms in mono- and multifactorial cardiomyopathies. <i>Pharmacogenomics</i> , 2002, 3, 367-378.	1.3	12
223	Join us. <i>European Journal of Heart Failure</i> , 2002, 4, 1-1.	7.1	1
224	Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. <i>European Journal of Heart Failure</i> , 2002, 4, 321-329.	7.1	69
225	Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects. <i>Journal of the American College of Cardiology</i> , 2002, 39, 2034-2041.	2.8	32
226	Relationships between the antihypertensive effects of bisoprolol and levels of plasma atrial natriuretic peptide in hypertensive patients. <i>Fundamental and Clinical Pharmacology</i> , 2002, 16, 361-368.	1.9	6
227	Are angiotensin II receptor antagonists indicated in chronic heart failure?. <i>Heart Failure Monitor</i> , 2002, 2, 85-7.	0.7	2
228	Thromboembolism in heart failure, old ideas and new challenges. <i>European Journal of Heart Failure</i> , 2001, 3, 265-269.	7.1	18
229	The heart of genomics. <i>Nature Medicine</i> , 2001, 7, 287-288.	30.7	3
230	Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. <i>American Journal of Cardiology</i> , 2000, 86, 417-421.	1.6	46
231	Homozygotes for a R869G Mutation in the $\beta^2$ -myosin Heavy Chain Gene have a Severe Form of Familial Hypertrophic Cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 2000, 32, 1575-1583.	1.9	59
232	Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2000, 35, 29-35.	2.8	74
233	Effects of Prolonged Propranolol Treatment on Left Ventricular Remodeling and Oxidative Stress After Myocardial Infarction in Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, 806-813.	1.9	16
234	Characterization of a Unique Genetic Variant in the $\beta^1$ -adrenoceptor Gene and Evaluation of its Role in Idiopathic Dilated Cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 1999, 31, 1025-1032.	1.9	103

#	ARTICLE	IF	CITATIONS
235	Genetic aspects of heart failure. <i>European Journal of Heart Failure</i> , 1999, 1, 121-126.	7.1	17
236	Familial dilated cardiomyopathy: clinical features in French families. <i>European Journal of Heart Failure</i> , 1999, 1, 353-361.	7.1	22
237	Genotype-phenotype analysis in four families with mutations in $\beta$ -myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy. <i>Human Mutation</i> , 1998, 12, 385-392.	2.5	41
238	Identification of two novel mutations in the ventricular regulatory myosin light chain gene ( MYL2 ) associated with familial and classical forms of hypertrophic cardiomyopathy. <i>Journal of Molecular Medicine</i> , 1998, 76, 208-214.	3.9	130
239	Clinical Features and Prognostic Implications of Familial Hypertrophic Cardiomyopathy Related to the Cardiac Myosin-Binding Protein C Gene. <i>Circulation</i> , 1998, 97, 2230-2236.	1.6	241
240	The Influence of the Angiotensin I Converting Enzyme Genotype in Familial Hypertrophic Cardiomyopathy Varies with the Disease Gene Mutation. <i>Journal of Molecular and Cellular Cardiology</i> , 1997, 29, 831-838.	1.9	110
241	Correlation Between Left Ventricular Hypertrophy and GAA Trinucleotide Repeat Length in Friedreich's Ataxia. <i>Circulation</i> , 1997, 95, 2247-2249.	1.6	83
242	Diagnostic Value of Electrocardiography and Echocardiography for Familial Hypertrophic Cardiomyopathy in a Genotyped Adult Population. <i>Circulation</i> , 1997, 96, 214-219.	1.6	143
243	Muscular blood flow response to submaximal leg exercise in normal subjects and in patients with heart failure. <i>Journal of Applied Physiology</i> , 1996, 81, 2571-2579.	2.5	36
244	Codon 102 of the Cardiac Troponin T Gene Is a Putative Hot Spot for Mutations in Familial Hypertrophic Cardiomyopathy. <i>Circulation</i> , 1996, 94, 3069-3073.	1.6	99
245	Cardiac myosin binding protein C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. <i>Nature Genetics</i> , 1995, 11, 438-440.	21.4	417
246	Doppler Echocardiography in Familial Hypertrophic Cardiomyopathy. <i>Echocardiography</i> , 1995, 12, 235-241.	0.9	14
247	Molecular Basis of Familial Cardiomyopathies. <i>Circulation</i> , 1995, 91, 532-540.	1.6	140
248	Exclusion of HRAS from long QT locus. <i>Nature Genetics</i> , 1994, 8, 113-114.	21.4	25
249	Identification of a Mutation Near a Functional Site of the $\beta$ cardiac myosin Heavy Chain Gene in a Family with Hypertrophic Cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 1994, 26, 1241-1247.	1.9	16
250	Genetics of familial hypertrophic cardiomyopathy. <i>Trends in Cardiovascular Medicine</i> , 1993, 3, 115-118.	4.9	6
251	Spontaneous and evoked release of atrial natriuretic peptide from the rat atria in vitro. <i>Journal of the American College of Cardiology</i> , 1990, 15, A77.	2.8	0